Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aura Biosciences Inc (AURA)

Aura Biosciences Inc (AURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 409,594
  • Shares Outstanding, K 63,503
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,920 K
  • EBIT $ -113 M
  • EBITDA $ -112 M
  • 60-Month Beta 0.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 763.79% (-51.19%)
  • Historical Volatility 54.62%
  • IV Percentile 94%
  • IV Rank 73.70%
  • IV High 1,011.45% on 11/04/25
  • IV Low 69.92% on 03/17/25
  • Expected Move (DTE 14) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 717
  • Open Int (30-Day) 672
  • Expected Range 6.49 to 6.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.43
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.45
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +17.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.18 +24.44%
on 11/07/25
6.62 -2.73%
on 11/28/25
+1.00 (+18.38%)
since 11/05/25
3-Month
5.18 +24.44%
on 11/07/25
6.72 -4.18%
on 09/12/25
-0.04 (-0.62%)
since 09/05/25
52-Week
4.34 +48.22%
on 05/15/25
9.14 -29.54%
on 12/11/24
-1.84 (-22.22%)
since 12/05/24

Most Recent Stories

More News
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ...

AURA : 6.48 (+0.47%)
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The...

FDMT : 10.85 (-3.04%)
NBP : 4.14 (+3.76%)
AURA : 6.48 (+0.47%)
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential...

AURA : 6.48 (+0.47%)
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc.  (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ...

AURA : 6.48 (+0.47%)
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with...

AURA : 6.48 (+0.47%)
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

AURA : 6.48 (+0.47%)
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

AURA : 6.48 (+0.47%)
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

AURA : 6.48 (+0.47%)
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

AURA : 6.48 (+0.47%)
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

AURA : 6.48 (+0.47%)

Business Summary

Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based...

See More

Key Turning Points

3rd Resistance Point 6.90
2nd Resistance Point 6.72
1st Resistance Point 6.58
Last Price 6.48
1st Support Level 6.26
2nd Support Level 6.08
3rd Support Level 5.94

See More

52-Week High 9.14
Fibonacci 61.8% 7.31
Fibonacci 50% 6.74
Last Price 6.48
Fibonacci 38.2% 6.18
52-Week Low 4.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar